Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.

Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC.

Cancer Res. 2010 Mar 1;70(5):1845-53. doi: 10.1158/0008-5472.CAN-09-3613. Epub 2010 Feb 16. Erratum in: Cancer Res. 2010 Apr 15;70(8):3414.

PMID:
20160032
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
[PubMed - indexed for MEDLINE]
3.

Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenase activity by ethyl pyruvate.

Vasilyeva ED, Kaledin V, Nikolin VP, Popova NA, Kirilyuk IA, Grigor'ev IA.

Exp Oncol. 2012;34(1):66-8.

PMID:
22453153
[PubMed - indexed for MEDLINE]
4.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10.

PMID:
23752227
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

PMID:
17234791
[PubMed - indexed for MEDLINE]
Free Article
6.

p-Coumaric acid inhibits indoleamine 2, 3-dioxygenase expression in murine dendritic cells.

Kim SI, Jeong YI, Jung ID, Lee JS, Lee CM, Yoon MS, Seong EY, Kim JI, Lee JD, Park YM.

Int Immunopharmacol. 2007 Jun;7(6):805-15. Epub 2007 Feb 27.

PMID:
17466914
[PubMed - indexed for MEDLINE]
7.

Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC.

Mol Cancer Ther. 2010 Jun;9(6):1864-71. doi: 10.1158/1535-7163.MCT-10-0185. Epub 2010 Jun 8.

PMID:
20530717
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA.

Blood. 2010 Apr 29;115(17):3520-30. doi: 10.1182/blood-2009-09-246124. Epub 2010 Mar 2.

PMID:
20197554
[PubMed - indexed for MEDLINE]
Free Article
9.

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS.

Mol Cancer Ther. 2010 Feb;9(2):489-98. doi: 10.1158/1535-7163.MCT-09-0628. Epub 2010 Feb 2.

PMID:
20124451
[PubMed - indexed for MEDLINE]
Free Article
10.

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JL.

J Clin Invest. 2008 Jul;118(7):2562-73. doi: 10.1172/JCI34712.

PMID:
18568076
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ.

Cancer Discov. 2012 Aug;2(8):722-35. doi: 10.1158/2159-8290.CD-12-0014. Epub 2012 Jul 19.

PMID:
22822050
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Katz JB, Muller AJ, Prendergast GC.

Immunol Rev. 2008 Apr;222:206-21. doi: 10.1111/j.1600-065X.2008.00610.x. Review.

PMID:
18364004
[PubMed - indexed for MEDLINE]
13.

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ.

J Med Chem. 2008 Mar 27;51(6):1706-18. doi: 10.1021/jm7014155. Epub 2008 Mar 5. Erratum in: J Med Chem. 2008 Nov 27;51(22):7325.

PMID:
18318466
[PubMed - indexed for MEDLINE]
14.

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.

Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F.

Gynecol Oncol. 2009 Nov;115(2):185-92. doi: 10.1016/j.ygyno.2009.07.015. Epub 2009 Aug 8.

PMID:
19665763
[PubMed - indexed for MEDLINE]
15.

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.

Liu X, Newton RC, Friedman SM, Scherle PA.

Curr Cancer Drug Targets. 2009 Dec;9(8):938-52. Review.

PMID:
20025603
[PubMed - indexed for MEDLINE]
16.

Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.

Ou X, Cai S, Liu P, Zeng J, He Y, Wu X, Du J.

J Cancer Res Clin Oncol. 2008 May;134(5):525-33. Epub 2007 Oct 2.

PMID:
17909857
[PubMed - indexed for MEDLINE]
17.

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F.

Clin Cancer Res. 2008 Nov 15;14(22):7251-9. doi: 10.1158/1078-0432.CCR-08-0991.

PMID:
19010841
[PubMed - indexed for MEDLINE]
Free Article
18.

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8. doi: 10.1073/pnas.0806173105. Epub 2008 Oct 24.

PMID:
18952840
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.

Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S.

J Exp Ther Oncol. 2003 Nov-Dec;3(6):336-45.

PMID:
14678522
[PubMed - indexed for MEDLINE]
20.

Inhibition of increased indoleamine 2,3-dioxygenase activity attenuates Toxoplasma gondii replication in the lung during acute infection.

Murakami Y, Hoshi M, Hara A, Takemura M, Arioka Y, Yamamoto Y, Matsunami H, Funato T, Seishima M, Saito K.

Cytokine. 2012 Aug;59(2):245-51. doi: 10.1016/j.cyto.2012.04.022. Epub 2012 May 18.

PMID:
22609210
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk